The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal antibody therapy bamlanivimab and etesevimab is currently not authorized to treat or prevent COVID-19 in any U.S. region because it is not effective against the omicron variant. However, the Department of Health and Human Services and FDA recommend retaining both products in case future COVID-19 variants are susceptible to them, and are evaluating whether to extend the shelf life for etesevimab in the future.

In other news, FDA last week released a screening checklist and drug interaction tool to help prescribers identify patients eligible for the Pfizer COVID-19 antiviral pill Paxlovid; and a dashboard summarizing data from its project to track SARS-CoV-2 variants from wastewater samples. 

The agency also alerted health care providers that certain hemodialysis machines made by Fresenius Medical Care may expose patients to toxic chemicals, and recommended certain actions to ensure patients continue to receive needed care.

Related News Articles

Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…
Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…
Blog
In June, we traveled to Fajardo, Puerto Rico to attend the annual convention for the territory’s College of Health Services Administrators, known as CASS.…
Headline
The Centers for Disease Control and Prevention last night endorsed the two-dose Novavax COVID-19 vaccine as a COVID-19 vaccine primary series for…